Phase 4
Completed N=43
The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Source: ClinicalTrials.gov NCT03782701 ↗
Enrolled (actual)
43
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of the research is to see if Lumify™ has an effect on eyelid position.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Palpebral Fissure Height |
9.64; 9.66; 9.92; 9.96; 9.85; 9.96 | — |
| SECONDARY Intraocular Pressure |
16.54; 16.70; 15.54; 15.58 | — |
| SECONDARY Eye Redness |
24; 25; 17; 16; 2; 2 | — |
| SECONDARY Eye Discomfort |
43; 43; 0; 0; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Adults age 18 and above able to provide informed consent to participate
- Subject with stable ocular health, defined as no ocular conditions requiring ongoing topical therapy or recent surgical intervention
Exclusion Criteria
- Adults unable to consent
- Prisoners
- Pregnant women.
- Known contradictions or sensitivities to study medication (brimonidine)
- Ocular surgery within the past 3 months or refractive surgery within the past six months
- Grossly abnormal lid margins, anatomical abnormalities, previous eyelid or orbital surgery
- Variable ptosis or eyelid position (e.g., myasthenia gravis, thyroid eye disease, or blepharospasm)
- Significant pre-existing ptosis of any cause (defined as margin reflex distance 1 < 1mm)
- Any ocular or systemic condition that, in the opinion of the investigator, would confound study data, interfere with the subject's study participation, or affected the subject's safety or trial parameters
- Presence of an active ocular infection
- Prior (within 5 days of beginning study treatment) use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines (including over the counter and herbal topical ophthalmic medications), phenylephrine dilating drops, any other topical ophthalmic agents
- Inability to sit comfortably for 15 - 30 minutes
Data sourced from ClinicalTrials.gov (NCT03782701). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.